ADAPTIVE CLINICAL TRIALS

TABLE OF CONTENTS

2 The Adaptive Concept
   Exhibit 1. Problems in clinical development
   Exhibit 2. Adaptive designs currently in use

4 Benefits of Adaptive Trials
   Exhibit 3. Why Drugs Fail in Phase 3
   Exhibit 4. Sample Size Reduction with Adaptive Designs
   Exhibit 5. Old Drug Development Paradigm
   Exhibit 6. New Drug Development Paradigm

8 Adaptive or Not?
   Exhibit 7. Regulatory Concerns
THE ADAPTIVE CONCEPT

THE CLINICAL DEVELOPMENT OF DRUGS and devices is a challenging task, and more so than product development activity in most other industries. The technical challenges are huge because understanding of the biological systems involved is usually incomplete. The complexity is significant because patients vary significantly from one another and are unpredictable in their responses. Additionally, every sponsor has to contend with the need for speed because of competition and the existence of budgetary pressures arising from the need to get a good return on investment in clinical development. The result is well known: success rates overall are low, New Drug Applications are too few, and the return on investment is abysmal. See Exhibit 1 for data on problems in clinical development.

A highly promising approach to re-thinking how clinical development is done is the adaptive clinical trial. What is it? In a conventional or “fixed” trial, all of the important details of the trial are decided before the trial starts, and are then not changed. The trial is completed, the data

Exhibit 1.
Problems in Clinical Development

- The biopharmaceutical industry worldwide spends $100 Billion per year on the clinical development of drugs, up from $33 Billion in 1999 [1].
- The number of NCEs and New BLAs approved by the FDA was 35 in 1999 and 20 in 2008 [2].
- 50% of Phase 3 trials are failures [3].
- 45% of Phase 3 industry trials have the wrong dose [4].
- Obtaining accurate estimates of variance in patient response data can reduce sample size by as much as 50% [5].
- Wasted medical supplies in typical conventional trials are 30% to 60% of the optimum. In an adaptive dose-finding trial, conventional planning methods can yield overages of 300% to 500% [6]. In some oncology trials, the cost of medical supplies can be as much as $100,000 per patient per year.
- 10% to 30% of clinical sites never recruit a patient, but nevertheless incur a set-up cost of around $70,000 per site. Data are not analyzed during the implementation stage of a trial to identify these sites [7].
- The largest single cost in clinical trials is site monitoring—as much as 30% of the total. However, real-time data are not available to optimize visit schedules, leading to large amounts of money wasted [8].
is analyzed, and if the results are positive, an NDA is submitted to the regulatory authorities. Unfortunately, in a large percentage of Phase 3 or “confirmatory” trials, the results are not positive, the trial is a failure, and the investment is unproductive. In an adaptive trial, in contrast, it is possible to look at the accruing data from patients at one or more times (called “interim looks” at the data) as the trial is on-going, and adjust certain parameters of the trial in order to increase the probability of success when the trial ends.

See Exhibit 2 for some of the adaptations now being tried.

**In an adaptive trial, it is possible to look at the accruing data from patients at one or more times as the trial is on-going.**
THE BENEFITS OF ADAPTIVE TRIALS FALL into three categories: commercial, ethical, and budgetary.

The commercial benefit is that much better information is obtained on the drug and its dosage, resulting in a much greater chance that the Phase 3 confirmatory trials will be successful, with a reduced probability that the Phase 3 dose will either be toxic or show inadequate efficacy. Exhibit 3 illustrates the potential for better information to reduce the rate of failure in Phase 3.

Another commercial benefit is that the time-to-market for a drug can be reduced by combining proof-of-concept trials (to show that the drug works) with dose-finding trials (to pick the right dose) or by combining dose-finding trials with confirmatory trials. This eliminates the “lost” time (also known as “white space”) between the end of one trial and the startup of the next. Being faster to market increases the Net Present Value (NPV) of the product.

The ethical benefit is that in both early-stage and late-stage trials, more patients will receive doses that work because doses with inadequate efficacy are adapted out. This benefit is both immediate (early stage) and deferred (late stage).

The budgetary benefit is that, frequently, the number of patients required in a Phase 2 trial can be reduced. See Exhibit 4 for an illustrative example from Eli Lilly.
### Exhibit 3.
**Why Drugs Fail in Phase 3**

<table>
<thead>
<tr>
<th>Reason for Attrition</th>
<th>Category</th>
<th>Phase 3 %</th>
<th>Questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy uncompetitive</td>
<td>Economic Reasons</td>
<td>18</td>
<td>Could we stop earlier? Was the dose right? Was the population right?</td>
</tr>
<tr>
<td>Safety uncompetitive</td>
<td>Economic Reasons</td>
<td>11</td>
<td>Were Phase 1 and Phase 2 thorough?</td>
</tr>
<tr>
<td>Lacks “strategic fit”</td>
<td>Economic Reasons</td>
<td>3</td>
<td>Why is the decision so late?</td>
</tr>
<tr>
<td>Market too small</td>
<td>Economic Reasons</td>
<td>8</td>
<td>Efficacy too low? Was the dose right? Was the population right?</td>
</tr>
<tr>
<td>Mfg cost too high</td>
<td>Economic Reasons</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Inadequate efficacy for FDA approval</td>
<td>Approvability Reasons</td>
<td>18</td>
<td>Was the dose right? Was the sample size right? Was the population right?</td>
</tr>
<tr>
<td>Inadequate safety for FDA approval</td>
<td>Approvability Reasons</td>
<td>13</td>
<td>Was the dose right? Was the population right? Were Phase 1 and Phase 2 thorough?</td>
</tr>
<tr>
<td>PK/bioavailability issues</td>
<td>Approvability Reasons</td>
<td>3</td>
<td>Was Pk/Pd work thorough?</td>
</tr>
<tr>
<td>Compound was backup</td>
<td>Approvability Reasons</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Chemistry/control issue</td>
<td>Approvability Reasons</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td>13</td>
<td></td>
</tr>
</tbody>
</table>

Source: Cytel Analysis of Boston Consulting Group Data
At its core, the idea behind adaptive trials is simple and compelling: reduce the uncertainty in clinical development that leads to flawed trial designs by getting additional information (beyond what one had at the beginning of the trial) from the ongoing trial. Additional information is always better, leading to better decisions about what to do during the course of clinical development. More opportunities to refine decisions are also a benefit. See Exhibits 5 and 6.

In practice, however, adaptive designs have attendant challenges so that the adaptive route may not be the right one for every trial. A thorough evaluation is needed to determine in any given instance the best choice of design, whether adaptive or not.

**Exhibit 4.**

**Sample Size Reduction with Adaptive Designs**

<table>
<thead>
<tr>
<th>TREATMENT GROUP</th>
<th>REAL TRIAL</th>
<th>RETROSPECTIVE ADAPTIVE DESIGN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haloperidol IM</td>
<td>126</td>
<td>60</td>
</tr>
<tr>
<td>Olanzapine IM</td>
<td>131</td>
<td>66*</td>
</tr>
<tr>
<td>Placebo IM</td>
<td>54</td>
<td>30</td>
</tr>
</tbody>
</table>

Trial stopped: criteria met to declare olanzapine IM superior to placebo and non-inferior to haloperidol IM

*note: max value based on prior sensitivity analysis (min=62)

Source: Stacy Lindborg, Eli Lilly, presentation to FDA/Industry workshop

---

**Reduce the uncertainty in clinical development that leads to flawed trial designs by getting additional information from the ongoing trial.**
**Exhibit 5.**
**Old Drug Development Paradigm**

**PHASE 1**

**PHASE 2**

**PHASE 3**

- Budgets allocated by phase
- Few decision-making opportunities

**Exhibit 6.**
**New Drug Development Paradigm**

**EARLY DEVELOPMENT**

**REGISTRATION DEVELOPMENT**

- Integrated budget allocation along a program
- Many decision-making and design optimization opportunities
IT IS USEFUL TO THINK OF THE DECISION on whether to make a trial adaptive or not as passing through three gates with gatekeepers who may not let you through.

The first gate is owned by regulatory agencies. One needs to show them the logic for doing an adaptive design and, if they accept the logic, that the statistics have been done correctly (“show me that you have controlled the Type I error”), and if they accept that, that the possibility of bias and manipulation of the trial have been minimized. See Exhibit 7 for a summary of regulatory concerns.

The clinical operations team owns the second gate. They will want to know whether all of the operational challenges of an adaptive trial have been dealt with. These range from the need to make accurate data available on time for interim analyses, to the need to ensure there is adequate medical supply at all sites (but not too much, for overages could be very expensive), and to the need put in place an interim monitoring body such as a Data Monitoring Committee to make sure that the “unblinded” data they see are not seen by those who should not.

The finance staff owns the third gate. They will want to know if the adaptive trial is going to cost more or less than a conventional trial and, if it is potentially more, why the added cost is justified.

Exhibit 7.
Regulatory Concerns
A Summary

- Rationale for adaptive design – is it a cover for sloppiness in design or is there a provable need and benefit?
- Control of Type I error. “Show me.”
- Adaptations defined in advance
- Protocol for interim monitoring known in advance, proves that potential for bias is virtually eliminated
- After-the-fact proof that the protocol and interim monitoring procedures were followed (audit capability)
We find it useful to take these three gates and convert them into ten questions to answer in deciding “Adaptive Or Not”.

1. First, and most importantly, what is the timing of observation of the key endpoint upon which to base adaptation and what is the expected enrollment rate? More specifically, is there sufficient time between the observation of a sufficient number of patients’ endpoints and the enrollment of the last patient to afford opportunity for adaptation? Cytel can assist you in making this assessment.

2. If answer to 1 is “no”, is there a sufficiently reliable surrogate or biomarker that is observable early enough upon which adaptation could be based?

3. Are there any regulatory concerns / reservations which would prohibit use of an Adaptive Design (AD)? To answer this question, consultation with regulatory affairs personnel, and/or those experienced in dealing with regulatory agencies, may be required. Cytel can help you in making this assessment.

4. Will sufficient safety data be available at filing if Adaptive Design is used? That is, will the number of patients required by regulatory agencies to support the safety of the candidate product be available at expected time of filing? If the adaptive design provides fewer patients than required for completion of the required safety database, the sample size may need to be increased beyond that necessary for the adaptive design.

5. Is there sufficient drug supply (for all potential doses & durations) to support all possible adaptations? Cytel has the technology to help you to make this assessment.

6. Can the needed drug supply be made available at the sites when necessary to support all possible adaptations? How can one do this without either the risk of stockouts or the cost of massive overage and waste? See Cytel’s presentation on how to meet the challenges of drug supply in an adaptive trial. [Link]

7. Is data acquisition to inform on the planned adaptations rapid enough so the required analyses to inform the adaptation can be completed in time? Cytel can help you make this assessment.

8. Is there sufficient statistical expertise to support the evaluation of design options so that the Adaptive Design can be properly evaluated and implemented? Cytel can provide this expertise if a sponsor does not possess it.
9. Is the software necessary for evaluation and implementation of Adaptive Design options available? Adaptive design performance characteristics must be thoroughly summarized prior to protocol approval. Software for closed form calculations and/or simulations is necessary to document these characteristics, and must be available in time to support the protocol development, and then to execute the necessary adaptive design calculations during the trial. Cytel’s East and Compass software are industry standards for both adaptive and non-adaptive designs. In addition, Cytel has a large suite of validated proprietary software that can be applied to unusual situations where the standard software is not adequate.

Software is needed that facilitates the interim monitoring process while satisfying regulatory concerns about bias. Software is also needed to make the adaptive changes happen – communicating what the changes are to the IVRS system, and making sure that the necessary doses are available at every site where they may be needed.

10. Does the use of Adaptive Design in comparison to a classical alternative non-Adaptive Design afford sufficient improvement on cost, time to complete, and/or quantity / quality of information to favor the use of Adaptive Design? In order to answer this question, one should have a full evaluation of the costs, the time to complete, and the quantity and quality of information expected from the candidate adaptive design and the non-adaptive-design alternative. With this information, a design can be chosen to balance among these aspects of each of the design candidates. Cytel can help you in making this comparison.

Given the potential benefits of adaptive designs, we believe it makes sense for a sponsor to evaluate the adaptive alternative for their clinical trial to determine whether the benefits offered are significant and are worth the additional regulatory and operational complexity. Cytel has the experience to help you make this assessment. We will help you make the correct choice.

See the white paper on ACES, our best-in-class system for adaptive trial implementation.

See case studies.
REFERENCES

2. fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/default.htm
3. Janet Woodcock, FDA Acting Deputy Commissioner, FDA/Industry Workshop, September 2004
5. PHT and palmOne Client Success Story--Merck Research Laboratories Insomnia Study, phtcorp.com/pdf/merck_case_study.pdf